NEW YORK, Jan. 15-Abbott Laboratories will develop and distribute assays and instruments using Luminex's bead-based xMAP technology, the two companies said today.
The companies have signed two agreements that grant Abbott the right to license, supply and distribute Luminex biological testing technologies, develop new products, and purchase and distribute existing Luminex products.
Luminex will receive an upfront license fee from Abbott and royalties on commercialized assays and instruments. Abbott will also directly purchase Luminex 100 systems and xMAP microspheres.
The company's xMAP system, which is based on microsphere analysis, allows for medium- and high-throughput multiplexed assays.
Luminex, based in Austin, Tex., is publicly held.
For further information, see the company statement.